Company News

Mar. 26 2025

Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for Its Epigenetic Reprogramming Therapies

Dec. 3 2024

Turn Biotechnologies Announces Landmark Study to Assess Effectiveness of ERA™ Therapy in Restoring Bone Marrow

Oct. 1 2024

Veteran Drug Developer Joins Turn Biotechnologies to Lead Pre-clinical Development Efforts

Sept. 4 2024

Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week

May 28 2024

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

May 7 2024

Turn Biotechnologies Discussed Emerging Therapies at Aesthetic Plastic Surgery Society Meeting

Jan. 3 2024

Turn Biotechnologies' Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry

Nov. 7 2023

Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, with No Distribution to Other Organs

Oct. 25 2023

FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic

Aug. 28 2023

Turn Biotechnologies Co-Founder to Present at Prestigious ARDD Meeting in Copenhagen

Aug. 14 2023

Turn Biotechnologies Cell Reprogramming Treatment Showcased in AAD’s First Session on Regenerative Therapies

June 12 2023

Epigenetic Reprogramming Safe, Effective in Skin Using eTurna™ Delivery System: SEASON Conference Presentation

June 5 2023

Turn Biotechnologies Founder to be Featured Speaker at Japanese Society of Anti-Aging Medicine Meeting

May 10 2023

Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin

May 9 2023

Turn Biotechnologies to Present at the JMP Securities Life Sciences Conference

May 1 2023

Turn Biotechnologies Shows Promise of Epigenetic Reprogramming to Rejuvenate Skin at SEASON Aesthetic Conference

Apr. 25 2023

Turn Biotechnologies to Discuss Promise of Epigenetic Reprogramming in CAR-T Cell Therapy at World Oncology Cell Therapy Congress

Apr. 18 2023

Turn Biotechnologies to Present Data at AACR Showing Epigenetic Reprogramming with ERA™ Technology Improves T Cell Immunotherapy

Apr. 17 2023

Turn Biotechnologies Co-Founder to Present at Foresight Institute's Longevity Frontiers Workshop

Apr. 2023

Turn Biotechnologies Sharpens Immunology Focus by Adding Two Cell Therapy Specialists to its Medical Advisory Board

Apr. 2023

Turn Biotechnologies to Present at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

Feb. 2023

Turn Biotechnologies to Present at Next Generation CAR & T Cell Therapies Conference on February 28

Dec. 2022

Turn Biotechnologies Changes Paradigm in Skin Rejuvenation

Nov. 2022

Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer

Oct. 2022

T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness

Sept. 2022

Vittorio Sebastiano, Head of Turn Biotechnologies Research, to Present at Prestigious Cold Spring Harbor Laboratories

Sept. 2022

Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics

Aug. 2022

Prominent ophthalmologist will guide Turn Bio's search for therapies to cure eye diseases

Aug. 2022

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Apr. 2022

Global pharma organizations back Turn Biotechnologies to advance its cell rejuvenation program

Mar. 2022

Turn Bio adds veteran executives with decades of international business development, intellectual property expertise

Apr. 2021

Turn Biotechnologies completes latest round of funding

Feb. 2021

Turn Biotechnologies expands the potential of its mRNA platform by licensing unique artificial niche technology

Jan. 2021

Turn Biotechnologies Licenses Revolutionary Technology to Unwind the Effects of Aging at a Cellular Level

Mar. 2020

Research Shows Promise of Technology Used by Turn Biotechnologies to Develop Therapies for Age-Related Diseases